These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 24553177)

  • 41. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
    Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
    Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.
    Awata-Shiraiwa M; Yokohama A; Kanai Y; Gotoh N; Kasamatsu T; Handa H; Saitoh T; Murakami H; Hirato J; Ikota H; Tsukamoto N
    Acta Haematol; 2023; 146(5):384-390. PubMed ID: 36917966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Xu L; Hunter ZR; Yang G; Cao Y; Liu X; Manning R; Tripsas C; Chen J; Patterson CJ; Kluk M; Kanan S; Castillo J; Lindeman N; Treon SP
    Leukemia; 2014 Aug; 28(8):1698-704. PubMed ID: 24509637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
    Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
    Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
    [No Abstract]   [Full Text] [Related]  

  • 45. New treatment strategies for Waldenström macroglobulinemia.
    Moreno DF; de Larrea CF; Castillo JJ
    Clin Adv Hematol Oncol; 2022 Aug; 20(8):506-515. PubMed ID: 36125957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
    Poulain S; Roumier C; Venet-Caillault A; Figeac M; Herbaux C; Marot G; Doye E; Bertrand E; Geffroy S; Lepretre F; Nibourel O; Decambron A; Boyle EM; Renneville A; Tricot S; Daudignon A; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Clin Cancer Res; 2016 Mar; 22(6):1480-8. PubMed ID: 26490317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
    Castillo JJ; Xu L; Gustine JN; Keezer A; Meid K; Dubeau TE; Liu X; Demos MG; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2019 Nov; 187(3):356-363. PubMed ID: 31267520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell-free DNA analysis for detection of MYD88
    Demos MG; Hunter ZR; Xu L; Tsakmaklis N; Kofides A; Munshi M; Liu X; Guerrera ML; Leventoff CR; White TP; Flynn CA; Meid K; Patterson CJ; Yang G; Branagan AR; Sarosiek S; Castillo JJ; Treon SP; Gustine JN
    Am J Hematol; 2021 Jul; 96(7):E250-E253. PubMed ID: 33819355
    [No Abstract]   [Full Text] [Related]  

  • 52. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
    Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
    J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.
    Poulain S; Boyle EM; Roumier C; Demarquette H; Wemeau M; Geffroy S; Herbaux C; Bertrand E; Hivert B; Terriou L; Verrier A; Pollet JP; Maurage CA; Onraed B; Morschhauser F; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Br J Haematol; 2014 Nov; 167(4):506-13. PubMed ID: 25160558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.
    Landgren O; Tageja N
    Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.
    Ondrejka SL; Lin JJ; Warden DW; Durkin L; Cook JR; Hsi ED
    Am J Clin Pathol; 2013 Sep; 140(3):387-94. PubMed ID: 23955458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Waldenström macroglobulinemia: biology, genetics, and therapy.
    Paludo J; Ansell SM
    Blood Lymphat Cancer; 2016; 6():49-58. PubMed ID: 31360080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Waldenstrom macroglobulinemia: genetics dictates clinical course.
    Lenz G
    Blood; 2014 May; 123(18):2750-1. PubMed ID: 24786453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.